Another phase 3 study proved that anti-PD-L1 antibody sugemalimab plus chemotherapy extended progression-free survival (PFS) and overall survival (OS) in treatment-naïve late-stage patients with ESCC, indicating the curative efficacy of immune checkpoint blockade therapies [4]. Here, CD274 is linked to esophageal squamous cell carcinoma.